A5016243231- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer Research and Treatments
- Cancer Cells and Metastasis
- Economic and Financial Impacts of Cancer
- Cancer survivorship and care
- Cancer Genomics and Diagnostics
- Esophageal Cancer Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Diagnosis and Treatment
- Palliative Care and End-of-Life Issues
- Neutropenia and Cancer Infections
- Radiation Therapy and Dosimetry
- Health Systems, Economic Evaluations, Quality of Life
- Childhood Cancer Survivors' Quality of Life
- Atomic and Subatomic Physics Research
- Iron Metabolism and Disorders
- Global Cancer Incidence and Screening
- Complement system in diseases
- Healthcare Systems and Public Health
- Blood donation and transfusion practices
- Tracheal and airway disorders
- Telemedicine and Telehealth Implementation
- COVID-19 and healthcare impacts
- Neuroendocrine Tumor Research Advances
Case Western Reserve University
2023-2024
University Hospitals Seidman Cancer Center
2022-2024
University Hospitals of Cleveland
2022-2023
University School
2023
Abstract Purpose: A single arm, phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab (CNP) in metastatic triple-negative breast cancer (mTNBC) was designed to evaluate overall response rate (ORR), progression-free survival (PFS), duration (DOR), safety/tolerability, (OS), identify pathologic transcriptomic correlates therapy. Patients Methods: with ≤2 prior therapies for disease were treated CNP regardless tumor programmed cell death-ligand 1 status. Core tissue biopsies obtained...
Purpose: Disparities in cancer care delivery remain a pressing health-care crisis within the United States (US). The use of immune checkpoint inhibitors (ICIs) and their management may be disparity generator that impacts survival. This retrospective study assessed disparities cohort patients with variety solid tumors treated ICIs single organization focusing on impact race, socioeconomic status (SES) site survival development severe immune-related adverse events (irAEs). Patients Methods:...
<p>Genes associated with response to CNPs</p>
<p>Heat map of Hallmark Pathway Enrichment for each pairwise comparison radiographic response category (CR, PR, SD, PD)</p>
<div>AbstractPurpose:<p>A single arm, phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab (CNP) in metastatic triple-negative breast cancer (mTNBC) was designed to evaluate overall response rate (ORR), progression-free survival (PFS), duration (DOR), safety/tolerability, (OS), identify pathologic transcriptomic correlates therapy.</p>Patients Methods:<p>Patients with ≤2 prior therapies for disease were treated CNP regardless tumor programmed cell...
<p>Using single cell-RNA sequencing data from other investigations of response to anti-PD-1 chemo-immunotherapy in advanced TNBC validate association IGHG1 expression with treatment response.</p>
<p>Heat map of Reactome Pathway Enrichment (Top 25, Bottom and selected pathways) by pairwise comparison radiographic response category (CR, PR, SD, PD)</p>
<div>AbstractPurpose:<p>A single arm, phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab (CNP) in metastatic triple-negative breast cancer (mTNBC) was designed to evaluate overall response rate (ORR), progression-free survival (PFS), duration (DOR), safety/tolerability, (OS), identify pathologic transcriptomic correlates therapy.</p>Patients Methods:<p>Patients with ≤2 prior therapies for disease were treated CNP regardless tumor programmed cell...
<p>Genes associated with response to CNPs</p>
<p>Heat map of Hallmark Pathway Enrichment for each pairwise comparison radiographic response category (CR, PR, SD, PD)</p>
<p>Differential IGHG1 expression between the IGHG1high (highest tertile) versus IGHG1low (lower tertiles) groups</p>
<p>Heat map of Reactome Pathway Enrichment (Top 25, Bottom and selected pathways) by pairwise comparison radiographic response category (CR, PR, SD, PD)</p>
<p>Using single cell-RNA sequencing data from other investigations of response to anti-PD-1 chemo-immunotherapy in advanced TNBC validate association IGHG1 expression with treatment response.</p>
<p>Differential IGHG1 expression between the IGHG1high (highest tertile) versus IGHG1low (lower tertiles) groups</p>
8588 Background: Small cell lung cancer (SCLC) comprises 10-15% of all cancers yet little is known about the impact social determinants health (SDOH) on outcomes in patients with SCLC. This study aims to assess various SDOH overall survival (OS) diagnosed SCLC at a single institution. Methods: We have established large clinical/pathologic/genomic database and treated for between 1998-2022 our institution retrospective study. Demographic data including sex, race, age, stage, address, smoking...